重组干扰素治疗晚期乳腺癌
Recombinant interferon in advanced breast cancer.
作者信息
Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K
出版信息
Br J Cancer. 1984 May;49(5):615-20. doi: 10.1038/bjc.1984.96.
Abstract
Fifteen patients with locally advanced refractory breast cancer have been treated with recombinant leucocyte interferon ( rIFN -alpha A) for up to 12 weeks. Toxicity was considerable with the initial dosage schedule employed but became acceptable after reducing the starting dose by 50%. Minor side effects occurred in all patients and major CNS toxicity in six. Nine patients showed some evidence of tumour regression at 4 weeks. Only two of these were still responding at 12 weeks. Response was unrelated to the length of previous history, oestrogen receptor status or previous responsiveness to cytotoxic or hormone therapy.
摘要
15例局部晚期难治性乳腺癌患者接受了重组白细胞干扰素（rIFN-αA）治疗，疗程长达12周。采用最初的给药方案时毒性相当大，但在将起始剂量降低50%后毒性变得可以接受。所有患者均出现轻微副作用，6例出现严重中枢神经系统毒性。9例患者在4周时显示出一些肿瘤消退的迹象。其中只有2例在12周时仍有反应。反应与既往病史的长短、雌激素受体状态或既往对细胞毒性或激素治疗的反应无关。
相似文献
1
Recombinant interferon in advanced breast cancer.重组干扰素治疗晚期乳腺癌
Br J Cancer. 1984 May;49(5):615-20. doi: 10.1038/bjc.1984.96.
2
Neurological effects of recombinant human interferon.重组人干扰素的神经学效应
Br Med J (Clin Res Ed). 1983 Jan 22;286(6361):262-4. doi: 10.1136/bmj.286.6361.262.
3
A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer.重组α干扰素用于复发性或转移性乳腺癌患者的II期研究。
J Clin Oncol. 1984 Sep;2(9):1012-6. doi: 10.1200/JCO.1984.2.9.1012.
4
A phase I trial of recombinant leukocyte alpha 2 interferon in patients with advanced malignancy.
Am J Clin Oncol. 1985 Apr;8(2):97-107. doi: 10.1097/00000421-198504000-00001.
5
Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Cancer Treat Rep. 1985 May;69(5):547-9.
6
[Recombinant interferon alpha-2 (Sch 30500) in patients with head and neck cancer].
Gan To Kagaku Ryoho. 1985 Aug;12(8):1651-5.
7
Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
Cancer Treat Rep. 1986 Dec;70(12):1365-72.
8
Interferon in the treatment of cancer.
Med Clin North Am. 1986 May;Suppl:31-6. doi: 10.1016/s0025-7125(16)36785-2.
9
Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma.
J Clin Oncol. 1985 May;3(5):654-9. doi: 10.1200/JCO.1985.3.5.654.
10
[Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma].
Gan To Kagaku Ryoho. 1985 Aug;12(8):1625-9.
引用本文的文献
1
Type I Interferon in Chronic Virus Infection and Cancer.Ⅰ型干扰素在慢性病毒感染和癌症中的作用
Trends Immunol. 2017 Aug;38(8):542-557. doi: 10.1016/j.it.2017.05.005. Epub 2017 May 31.
2
Antitumour actions of interferons: implications for cancer therapy.干扰素的抗肿瘤作用：对癌症治疗的启示。
Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14.
3
Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Breast Cancer Res Treat. 1993;25(2):141-50. doi: 10.1007/BF00662139.
4
Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial.重组DNA人干扰素α2治疗晚期乳腺癌：一项2期试验
Br J Cancer. 1985 Jan;51(1):55-60. doi: 10.1038/bjc.1985.8.
5
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy.低剂量β-干扰素对接受化疗的乳腺癌患者自然杀伤细胞活性的影响。
Cancer Immunol Immunother. 1987;24(1):86-91. doi: 10.1007/BF00199838.
6
Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen.重组人干扰素α可增加人乳腺癌细胞（ZR-75-1）中雌激素受体的表达，并使这些细胞对他莫昔芬的抗增殖作用敏感。
Br J Cancer. 1987 Mar;55(3):255-7. doi: 10.1038/bjc.1987.49.
7
Recombinant gamma interferon in advanced breast cancer: a phase II trial.
Invest New Drugs. 1986;4(4):377-81. doi: 10.1007/BF00173511.
8
A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.
Cancer Chemother Pharmacol. 1986;18(1):63-8. doi: 10.1007/BF00253067.
9
The role of interferons in the treatment of malignant neoplasms.干扰素在恶性肿瘤治疗中的作用。
Yale J Biol Med. 1989 May-Jun;62(3):271-90.
10
The antitumor effects of interferon.干扰素的抗肿瘤作用。
Med Oncol Tumor Pharmacother. 1986;3(3-4):223-30. doi: 10.1007/BF02934998.
本文引用的文献
1
Production of interferon by suspensions of human leucocytes.人白细胞悬液产生干扰素。
Proc Soc Exp Biol Med. 1961 Dec;108:799-803. doi: 10.3181/00379727-108-27072.
2
Neurological effects of recombinant human interferon.重组人干扰素的神经学效应
Br Med J (Clin Res Ed). 1983 Jan 22;286(6361):262-4. doi: 10.1136/bmj.286.6361.262.
3
Partial purification of human leukocyte interferon on a large scale.人白细胞干扰素的大规模部分纯化
Methods Enzymol. 1981;78(Pt A):499-505. doi: 10.1016/0076-6879(81)78161-8.
4
Human interferon--properties, clinical application, and production.
J Parenter Sci Technol. 1981 Sep-Oct;35(5):223-6.
5
Human leukocyte interferon produced by E. coli is biologically active.由大肠杆菌产生的人白细胞干扰素具有生物活性。
Nature. 1980 Oct 2;287(5781):411-6. doi: 10.1038/287411a0.
6
Human interferon production with diploid fibroblast cells grown on microcarriers.利用微载体上培养的二倍体成纤维细胞生产人干扰素。
Biotechnol Bioeng. 1979 Mar;21(3):433-42. doi: 10.1002/bit.260210306.
7
Production of human lymphoblastoid interferon.人淋巴母细胞干扰素的生产。
J Clin Microbiol. 1975 Jan;1(1):116-7. doi: 10.1128/jcm.1.1.116-117.1975.
Zotero 插件